Acuitas Investments LLC purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 172,732 shares of the company's stock, valued at approximately $2,980,000. Progyny accounts for about 2.5% of Acuitas Investments LLC's investment portfolio, making the stock its 18th largest holding. Acuitas Investments LLC owned about 0.20% of Progyny as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Everence Capital Management Inc. acquired a new stake in Progyny during the 3rd quarter worth approximately $173,000. Cetera Trust Company N.A grew its stake in shares of Progyny by 30.0% in the third quarter. Cetera Trust Company N.A now owns 7,210 shares of the company's stock worth $121,000 after acquiring an additional 1,665 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Progyny by 1,576.0% during the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock worth $42,991,000 after acquiring an additional 2,412,068 shares during the period. Louisiana State Employees Retirement System increased its position in shares of Progyny by 62.4% during the third quarter. Louisiana State Employees Retirement System now owns 38,000 shares of the company's stock worth $637,000 after acquiring an additional 14,600 shares during the period. Finally, State of Alaska Department of Revenue raised its stake in shares of Progyny by 397.7% in the third quarter. State of Alaska Department of Revenue now owns 44,819 shares of the company's stock valued at $751,000 after acquiring an additional 35,813 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company's stock.
Analyst Ratings Changes
PGNY has been the subject of several analyst reports. JPMorgan Chase & Co. upped their price target on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Truist Financial reaffirmed a "hold" rating and issued a $19.00 target price (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Barclays lowered their price target on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. Bank of America increased their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, February 11th. Finally, Canaccord Genuity Group lowered their target price on shares of Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research note on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Progyny currently has a consensus rating of "Hold" and an average target price of $25.83.
Check Out Our Latest Stock Analysis on PGNY
Insider Activity at Progyny
In other Progyny news, Chairman David J. Schlanger purchased 150,000 shares of Progyny stock in a transaction that occurred on Thursday, December 26th. The stock was purchased at an average price of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now directly owns 228,269 shares in the company, valued at $3,350,988.92. This trade represents a 191.65 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Peter Anevski purchased 209,500 shares of the firm's stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the purchase, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. This trade represents a 90.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.
Progyny Stock Performance
Shares of PGNY stock traded down $0.68 during mid-day trading on Friday, hitting $23.20. 1,243,035 shares of the stock were exchanged, compared to its average volume of 1,799,572. The stock's fifty day simple moving average is $19.84 and its two-hundred day simple moving average is $18.66. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of 40.00, a P/E/G ratio of 2.37 and a beta of 1.34. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $40.89.
Progyny Profile
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Featured Articles
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
